EUVIMEDEUVIMED entdecken
Open Access

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer

Biagio Ricciuti iD, Giuseppe Lamberti iD, Sreekar R Puchala, Navin R Mahadevan iD, Jia-Ren Lin, Joao V Alessi iD, Alexander Chowdhury, Yvonne Y Li, Xinan Wang, Liam Spurr, Federica Pecci, Alessandro Di Federico iD und 21 weitere

Journal of Clinical Oncology · 10.04.2024 · 42 (11) · 1311-1321

DOI: 10.1200/jco.23.00580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2024. Verfasst von Biagio Ricciuti und 32 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although immune checkpoint inhibitors (ICI) have extended survival in patients with non–small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently develops after an initial benefit. However, the mechanisms of AR to ICI in NSCLC are largely unknown. METHODS Comprehensive tumor genomic profiling, machine learning–based assessment of tumor-infiltrating lymphocytes, multiplexed immunofluorescence, and/or HLA-I immunohistochemistry (IHC) were performed on matched pre- and post-ICI tumor biopsies from patients with NSCLC treated with ICI at the Dana-Farber Cancer Institute who developed AR to ICI. Two additional cohorts of patients with intervening chemotherapy or targeted therapies between biopsies were included as controls. RESULTS We performed comprehensive genomic profiling and immunophenotypic characterization on samples from 82 patients with NSCLC and matched pre- and post-ICI biopsies and compared findings with a control cohort of patients with non-ICI intervening therapies between biopsies (chemotherapy, N = 32; targeted therapies, N = 89; both, N = 17). Putative resistance mutations were identified in 27.8% of immunotherapy-treated cases and included acquired loss-of-function mutations in STK11, B2M, APC, MTOR, KEAP1, and JAK1/ 2; these acquired alterations were not observed in the control groups. Immunophenotyping of matched pre- and post-ICI samples demonstrated significant decreases in intratumoral lymphocytes, CD3e + and CD8a + T cells, and PD-L1–PD1 engagement, as well as increased distance between tumor cells and CD8 + PD-1 + T cells. There was a significant decrease in HLA class I expression in the immunotherapy cohort at the time of AR compared with the chemotherapy ( P = .005) and the targeted therapy ( P = .01) cohorts. CONCLUSION These findings highlight the genomic and immunophenotypic heterogeneity of ICI resistance in NSCLC, which will need to be considered when developing novel therapeutic strategies aimed at overcoming resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansGenomicsImmunophenotypingKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2

Substanzen

Antineoplastic Agents, ImmunologicalKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2

Autor:innen und Institutionen

  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA.
  • Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA.
  • Ludwig Center at Harvard, Harvard Medical School, Boston, MA.
  • Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.

ORCID-Profile: Biagio Ricciuti, Giuseppe Lamberti, Navin R Mahadevan, Joao V Alessi, Alessandro Di Federico, Adriana P Barrichello, Malini Gandhi, Hersh Gupta, Kathleen L Pfaff, Emma L Welsh, Mizuki Nishino, Bruce E Johnson, Jason L Weirather, Ian D Dryg, Lynette M Sholl, Peter Sorger, Renato Umeton, Mark M Awad

Förderung

  • NCI NIH HHS

Zitieren

APA

Ricciuti, B., Lamberti, G., Puchala, S. R., Mahadevan, N. R., Lin, J. R., Alessi, J. V., Chowdhury, A., Li, Y. Y., Wang, X., Spurr, L., Pecci, F., Di Federico, A., Venkatraman, D., Barrichello, A. P., Gandhi, M., Vaz, V. R., Pangilinan, A. J., Haradon, D., Lee, E., …, & Awad, M. M. (2024). Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 42(11), 1311-1321. https://doi.org/10.1200/jco.23.00580

Vancouver

Ricciuti B, Lamberti G, Puchala SR, Mahadevan NR, Lin JR, Alessi JV, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2024;42(11):1311-1321. doi:10.1200/jco.23.00580

BibTeX
@article{Ricciuti2024,
  author = {Ricciuti, Biagio and Lamberti, Giuseppe and Puchala, Sreekar R and Mahadevan, Navin R and Lin, Jia-Ren and Alessi, Joao V and Chowdhury, Alexander and Li, Yvonne Y and Wang, Xinan and Spurr, Liam and Pecci, Federica and Di Federico, Alessandro and Venkatraman, Deepti and Barrichello, Adriana P and Gandhi, Malini and Vaz, Victor R and Pangilinan, Andy J and Haradon, Danielle and Lee, Elinton and Gupta, Hersh and Pfaff, Kathleen L and Welsh, Emma L and Nishino, Mizuki and Cherniack, Andrew D and Johnson, Bruce E and Weirather, Jason L and Dryg, Ian D and Rodig, Scott J and Sholl, Lynette M and Sorger, Peter and Santagata, Sandro and Umeton, Renato and Awad, Mark M},
  title = {Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {11},
  pages = {1311--1321},
  doi = {10.1200/jco.23.00580}
}
Kostenlos starten →